"10.1371_journal.pcbi.1003203","plos computational biology","2013-08-29T00:00:00Z","Niko Beerenwinkel; Hesam Montazeri; Heike Schuhmacher; Patrick Knupfer; Viktor von Wyl; Hansjakob Furrer; Manuel Battegay; Bernard Hirschel; Matthias Cavassini; Pietro Vernazza; Enos Bernasconi; Sabine Yerly; Jürg Böni; Thomas Klimkait; Cristina Cellerai; Huldrych F Günthard; The Swiss HIV Cohort Study","Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland; SIB Swiss Institute of Bioinformatics, Basel, Switzerland; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; Clinic for Infectious Diseases, Bern University Hospital, Bern, Switzerland; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland; Division of Infectious Diseases, Geneva University Hospital, Geneva, Switzerland; Division of Infectious Diseases, University Hospital Lausanne, Lausanne, Switzerland; Division of Infectious Diseases, Cantonal Hospital St. Gallen, St. Gallen, Switzerland; Division of Infectious Diseases, Regional Hospital Lugano, Lugano, Switzerland; Laboratory of Virology, University Hospital Geneva, Geneva, Switzerland; Swiss National Center for Retroviruses, Institute of Medical Virology, University of Zurich, Zurich, Switzerland; Institute for Medical Microbiology, University of Basel, Basel, Switzerland; Division of Immunology and Allergy, Centre Hospitalier Universitaire Vadois, Lausanne, Switzerland","Conceived and designed the experiments: NB PK VvW HFG. Performed the experiments: VvW HF MB BH MC PV EB SY JB TK CC HFG. Analyzed the data: NB HM HS PK VvW HFG. Contributed reagents/materials/analysis tools: VvW HF MB BH MC PV EB SY JB TK CC HFG. Wrote the paper: NB HM HS PK VvW HFG.","I have read the journals policy and have the following potential conflicts: HFG has been a medical adviser and/or consultant for GlaxoSmithKline, Abbott, Novartis, Boehringer Ingelheim, Gilead Sciences, Roche, Merck Sharp & Dohme, Tibotec, and Bristol-Myers Squibb, and has received unrestricted research, travel, and educational grants from Roche, Abbott, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, ViiV Healthcare, Tibotec and Merck Sharp & Dohme (all money sent to institution). SY has participated in advisory board of Bristol-Meyers Squibb, has received travel grants from ViiV and Merck Sharp & Dohme, and has been paid for development of educational presentations by Gilead. VvW was supported by a fellowship of the Novartis Foundation (formerly Ciba-Geigy Jubilee Foundation). HFs institution has received money from participation in advisory boards of ViiVHealthcare, Bristol-Myers Squibb, Gilead, Merck Sharp & Dome, Boehringer-Ingelheim, and Janssen, and has received unrestricted educational or research grants from Abbott, ViiV Healthcare, BMS, Roche, Gilead, Merck Sharp & Dome, and Janssen-Cilag. MB has been paid by ViiV, Gilead, and MSD for serving on advisory boards and his institution has received educational and research grants from ViiV, Boehringer, Gilead, Abbott, and Bristol-Meyers Squibb. MC has received travel grants from Abbott, Boehringer-Ingelheim, Gilead, and MSD. PV has been paid for consulting Bristol-Meyers Sqibb, Merck Sharp & Dohme, and Janssen, and for lecturing by Janssen and Gilead. EB has been paid by Boehringer Ingelheim, Gilead, Merck Sharp & Dohme, and ViiV for consultancy and board membership, and his institution has been paid by Janssen, Gilead, Abbott, Bristol-Meyers Squibb, and Merck Sharp & Dohme for board membership and consultancy.","2013","08","Niko Beerenwinkel","NB",17,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
